Recruiting
Phase 2
Phase 3

PF-07275315

Sponsor:

Pfizer

Code:

NCT07363694

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Not accepted

Interventions

PF-07275315 dose 1

PF-07275315-dose 2

Placebo

PF-07275315-dose 3

Study Details

Brief summary:

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

This study is seeking participants who:

  • Are 35 to 80 years old
  • Have had moderate-to-severe COPD for at least 12 months
  • Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months
  • Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months

All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.

PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.

Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic.

Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease

Study ID

NCT07363694

Start date

Feb 11, 2026

Status verified date

Aug, 2026

Completion date

Jan 16, 2031

Anticipated

Primary completion date

Oct 24, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition).
  • Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capacity \[FVC\] less than \[<\] 70 percent (%) and post-bronchodilator FEV1 % predicted <70%, but greater than equal to 30%).
  • Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months
  • Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.

Key Exclusion Criteria:

  • Significant pulmonary disease other than COPD.
  • Requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent.
  • Hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).
  • Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.

Study Design

Enrollment

1156 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase 3 Treatment Arm A

experimental: Phase 2 Treatment Arm B

experimental: Phase 2 Treatment Arm A

placebo comparator: Phase 3 Treatment Arm B

placebo comparator: Phase 2 Treatment Arm C

Interventions

PF-07275315 dose 1

SC injection dose 1

PF-07275315-dose 2

SC injection dose 2

Placebo

SC injection matched

PF-07275315-dose 3

SC injection dose 3

Primary outcome measure

  • Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24 [ Time Frame: Baseline to Week 24 ]
  • Phase 3 part: Annualized rate of moderate or severe ECOPD [ Time Frame: Baseline to Week 52 ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

University of Alabama at Birmingham Lung Health Center

Recruiting

Birmingham, Alabama, United States, 35233

SEC Clinical Research

Recruiting

Dothan, Alabama, United States, 36305

Pulmonary Associates of Mobile, P.C.

Recruiting

Mobile, Alabama, United States, 36608

Pulmonary Associates, PA

Recruiting

Phoenix, Arizona, United States, 85027

IMAX Clinical Trials

Recruiting

La Palma, California, United States, 90623

NewportNativeMD, Inc.

Recruiting

Newport Beach, California, United States, 92663

California Medical Research Associates

Recruiting

Northridge, California, United States, 91324

Institute of HealthCare Assessment d/b/a Apex Clinical Research

Recruiting

San Diego, California, United States, 92120

Finlay Medical Research

Recruiting

Greenacres City, Florida, United States, 33467

Clinical Research Specialists LLC

Recruiting

Kissimmee, Florida, United States, 34746

Advanced Pulmonary Research Institute

Recruiting

Loxahatchee Groves, Florida, United States, 33470

Reed Medical Research

Recruiting

Miami, Florida, United States, 33176

Renstar Medical Research

Recruiting

Ocala, Florida, United States, 34470

HCA Florida Ocala Imaging Center

Recruiting

Ocala, Florida, United States, 34471

Ocala Lung and Critical Care Associates

Recruiting

Ocala, Florida, United States, 34471

Renstar Medical Research

Recruiting

Ocala, Florida, United States, 34471

Coastal Medical Research Institute, LLC

Recruiting

St. Petersburg, Florida, United States, 33704

Coastal Pulmonary and Critical Care, P.L.C

Recruiting

St. Petersburg, Florida, United States, 33704

Clinical Research Trials of Florida, Inc.

Recruiting

Tampa, Florida, United States, 33607

Clinical Site Partners, LLC dba Flourish Research

Recruiting

Winter Park, Florida, United States, 32789

Cpcc-Research Llc

Recruiting

East Point, Georgia, United States, 30344

Centricity Research Rincon Pulmonology

Recruiting

Rincon, Georgia, United States, 31326

ASHA Clinical Research - Munster, LLC

Recruiting

Hammond, Indiana, United States, 46324

Methodist Hospital Southlake

Recruiting

Merrillville, Indiana, United States, 46410

Southern Clinical Research, LLC

Recruiting

Zachary, Louisiana, United States, 70791

Revival Research Institute, LLC

Recruiting

Dearborn, Michigan, United States, 48126

AA Medical Research Center

Recruiting

Flint, Michigan, United States, 48504

Revive Research Institute, Inc.

Recruiting

Southfield, Michigan, United States, 48075

Oakland Medical Research

Recruiting

Troy, Michigan, United States, 48085

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63108

Barnes-Jewish Hospital Investigational Drug Service

Recruiting

St Louis, Missouri, United States, 63110

Barnes-Jewish Hospital

Recruiting

St Louis, Missouri, United States, 63110

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Washington University School-Cardiovascular Imaging and Clinical Research Core Laboratory

Recruiting

St Louis, Missouri, United States, 63110

Henderson Clinical Trials

Recruiting

Henderson, Nevada, United States, 89052

Salem Chest Specialists

Recruiting

Winston-Salem, North Carolina, United States, 27103

Southeastern Research Center

Recruiting

Winston-Salem, North Carolina, United States, 27103

Clinical Research Associates of Central PA, LLC

Recruiting

DuBois, Pennsylvania, United States, 15801

Bogan Sleep Consultants, LLC

Recruiting

Columbia, South Carolina, United States, 29201

Velocity Clinical Research, Gaffney

Recruiting

Gaffney, South Carolina, United States, 29340

Clinical Research of Rock Hill

Recruiting

Rock Hill, South Carolina, United States, 29732

Velocity Clinical Research, Spartanburg

Recruiting

Spartanburg, South Carolina, United States, 29303

Health Concepts

Recruiting

Rapid City, South Dakota, United States, 57702

Clinical Trials Center of Middle Tennessee, LLC

Recruiting

Franklin, Tennessee, United States, 37067

Premier Research Center, LLC

Recruiting

Hendersonville, Tennessee, United States, 37075

South Texas Medical Research Institute, Inc., DBA TTS Research

Recruiting

Boerne, Texas, United States, 78006

Ten20 Clinical Research

Recruiting

Carrollton, Texas, United States, 75010

Horizon Clinical Research Group

Recruiting

Cypress, Texas, United States, 77429

Alina Clinical Trials, LLC.

Recruiting

Dallas, Texas, United States, 75209

Greater Heights & Memorial Pulmonary and Sleep

Recruiting

Houston, Texas, United States, 77008

Houston Pulmonary Sleep and Allergy Associates

Recruiting

Houston, Texas, United States, 77065

Sherman Clinical Research

Recruiting

Sherman, Texas, United States, 75090

Synergy Respiratory Care

Recruiting

Sherwood Park, Alberta, Canada, T8H 0N2

Dr. Syed Anees Medicine Professional Corporation

Recruiting

Windsor, Ontario, Canada, N8X 1T3

More Information

Sponsor

Pfizer

Last update posted

Aug 31, 2026

Last verified

Aug, 2026

Keywords

  • COPD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-13. This information was provided to ClinicalTrials.gov by Pfizer on 2026-08-31.